Dosing and uses of Brodalumab
Psoriasis
Pending FDA approval for moderate-to-severe plaque psoriasis and psoriatic arthritis
Pediatric dosage forms and strengths
Safety and efficacy not established
Pharmacology of Brodalumab
Mechanism of action
Monoclonal antibody that binds to the interleukin-17 (IL-17) receptor, thereby preventing IL-17 from activating the receptor
This action neutralizes the proinflammatory effects of the ligands IL-17-A, -F, -A/F, and -e
IL-17 is part of a transmembrane receptor family that is involved in normal inflammatory and immune responses and plays a key role in the pathogenesis of plaque psoriasis
